Hematopoietic stem cell gene therapy: Assessing the relevance of preclinical models

Seminars in Hematology

Volumn 50, Issue 2, 2013, Pages 101-130

  Larochelle, Andre ^a   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FIBRONECTIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN BETA CHAIN; LENTIVIRUS VECTOR; MELPHALAN; RETROVIRUS VECTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENOLEUKODYSTROPHY; ARTICLE; BETA THALASSEMIA; CELL RENEWAL; CHRONIC GRANULOMATOUS DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG MEGADOSE; ERYTHROPOIESIS; GAUCHER DISEASE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; GENETIC TRANSDUCTION; GENOTOXICITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; WISKOTT ALDRICH SYNDROME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL;

EID: 84884679683     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.025     Document Type: Article

References (309)

1. Becker A.J., McCulloch E.A., Till J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197:452-454.
2. Till J.E., McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-222.
3. Larochelle A., Dunbar C.E. Genetic manipulation of hematopoietic stem cells. Semin Hematol 2004, 41:257-271.
4. Micklem H.S., Ford C.E., Evans E.P., Gray J. Interrelationships of myeloid and lymphoid cells: studies with chromosome-marked cells transfused into lethally irradiated mice. Proc R Soc Lond B Biol Sci 1966, 165:78-102.
5. Abramson S., Miller R.G., Phillips R.A. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 1977, 145:1567-1579.
6. Becker A.J., McCulloch E.A., Till J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197:452-454.
7. Ford C.E., Hamerton J.L., Barnes D.W., Loutit J.F. Cytological identification of radiation-chimaeras. Nature 1956, 177:452-454.
8. Wu A.M., Till J.E., Siminovitch L., McCulloch E.A. Cytological evidence for a relationship between normal hemotopoietic colony-forming cells and cells of the lymphoid system. J Exp Med 1968, 127:455-464.
9. Dick J.E., Magli M.C., Huszar D., Phillips R.A., Berstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of w/wv mice. Cell 1985, 42:71-79.
10. Jordan C.T., Lemischka I.R. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev 1990, 4:220-232.
11. Keller G., Paige C., Gilboa E., Wagner E.F. Expression of a foriegn gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature 1985, 318:149-154.
12. Lemischka I.R., Raulet D.H., Mulligan R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986, 45:917-927.
13. Roe T.-Y., Reynolds T.C., Yu G., Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993, 12:2099-2108.
14. Nolta J.A., Smogorzewska E.M., Kohn D.B. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood 1995, 86:101-105.
15. Kaleko M., Garcia J.V., Osborne W.R.A., Miller A.D. Expression of human adenosine deaminase in mice after transplantation of genetically-modified bone marrow. Blood 1990, 75:1733-1739.
16. Lim B., Apperly J.F., Orkin S.H., Williams D.A. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A 1989, 86:8892-8897.
17. Moore K.A., Fletcher F.A., Villalon D.K., Utter A.E., Belmont J.W. Human adenosine deaminase expression in mice. Blood 1990, 75:2085-2092.
18. Osborne W.R., Hock R.A., Kaleko M., Miller A.D. Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Hum Gene Ther 1990, 1:31-41.
19. Van Beusechem V.W., et al. Expression of human adenosine deaminase in mice transplanted with hematopoietic stem cells infected with amphotropic retroviruses. J Exp Med 1990, 172:729-736.
20. Wilson J.M., Danos O., Grossman M., Raulet D.H., Mulligan R.C. Expression of human adenosine deaminase in mice reconstituted with retrovirus-transduced hematopoietic stem cells. Proc Natl Acad Sci U S A 1990, 87:439-445.
21. Karlsson S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 1991, 78:2481-2492.
22. Lo M., et al. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 1999, 94:3027-3036.
23. Otsu M., et al. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 2000, 1:145-153.
24. Soudais C., et al. Stable and functional lymphoid reconstitution of common cytokine receptor γ chain deficient mice by retroviral-mediated gene transfer. Blood 2000, 95:3071-3077.
25. Bunting K.D., Sangster M.Y., Ihle J.N., Sorrentino B.P. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998, 4:58-64.
26. Otsu M., et al. Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells. Blood 2002, 100:1248-1256.
27. Yates F., et al. Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency. Blood 2002, 100:3942-3949.
28. Tybulewicz V.L., et al. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 1992, 357:407-410.
29. Correll P.H., et al. Expression of human glucocerebrosidase in long-term reconstituted mice following retroviral-mediated gene transfer into hematopoietic stem cells. Hum Gene Ther 1990, 1:277-283.
30. Correll P.H., Colilla S., Dave H.P., Karlsson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood 1992, 80:331-336.
31. Correll P.H., Fink J.K., Brady R.O., Perry L.K., Karlsson S. Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells. Proc Natl Acad Sci U S A 1989, 86:8912-8916.
32. Nolta J.A., Sender L.S., Barranger J.A., Kohn D.B. Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transfer. Blood 1990, 75:787-797.
33. Ohashi T., et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci U S A 1992, 89:11332-11336.
34. Weinthal J., et al. Expression of human glucocerebrosidase following retroviral vector-mediated transduction of murine hematopoietic stem cells. Bone Marrow Transplant 1991, 8:403-412.
35. Bender M.A., Gelinas R.E., Miller A.D. A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells. Mol Cell Biol 1989, 9:1426-1434.
36. Bodine D.M., Karlsson S., Nienhuis A.W. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci U S A 1989, 86:8897-8901.
37. Cone R.D., Weber-Benarous A., Baorto D., Mulligan R.C. Regulated expression of a complete human Β-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 1987, 7:887-897.
38. Dzierzak E.A., Papayannopoulou T., Mulligan R.C. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988, 331:35-41.
39. Karlsson S., Bodine D.M., Perry L., Papayannopoulou T., Nienhuis A.W. Expression of the human Β-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice. Proc Natl Acad Sci U S A 1988, 85:6062-6066.
40. Karlsson S., Papayannopoulou T., Schweiger S.G., Stamatoyannopoulos G., Nienhuis A.W. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc Natl Acad Sci U S A 1987, 84:2411-2415.
41. Li C.L., Dwarki V.J., Verma I.M. Expression of human alpha-globin and mouse/human hybrid beta-globin genes in murine hemopoietic stem cells transduced by recombinant retroviruses. Proc Natl Acad Sci U S A 1990, 87:4349-4353.
42. Cavazzana-Calvo M., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
43. Jirapongsananuruk O., Niemela J.E., Malech H.L., Fleisher T.A. CYBB mutation analysis in X-linked chronic granulomatous disease. Clin Immunol 2002, 104:73-76.
44. Dinauer M.C., Li L.L., Björgvinsdóttir H., Ding C., Pech N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 1999, 94:914-922.
45. Bjorgvinsdottir H., et al. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 1997, 89:41-48.
46. Dinauer M.C., Gifford M.A., Pech N., Li L.L., Emshwiller P. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 2001, 97:3738-3745.
47. Johnston R.B., Harbeck R.J., Johnston R.B. Recurrent severe infections in a girl with apparently variable expression of mosaicism for chronic granulomatous disease. J Pediatr 1985, 106:50-55.
48. Mardiney M., et al. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 1997, 89:2268-2275.
49. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 78:635-644.
50. Notarangelo L.D., Miao C.H., Ochs H.D. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008, 15:30-36.
51. Puck J.M., Candotti F. Lessons from the Wiskott-Aldrich syndrome. N Engl J Med 2006, 355:1759-1761.
52. Strom T.S., et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood 2003, 102:3108-3116.
53. Klein C., et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003, 101:2159-2166.
54. Cassel A., Cottler-Fox M., Doren S., Dunbar C.E. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol 1993, 21:585-591.
55. Hughes P.F.D., Eaves C.J., Hogge D.E., Humphries R.K. High efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture. Blood 1989, 74:1915-1922.
56. Larochelle A., et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996, 2:1329-1337.
57. Fink J.K., Correll P.H., Perry L.K., Brady R.O., Karlsson S. Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc Natl Acad Sci U S A 1990, 87:2334-2338.
58. Bordignon C., et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther 1993, 4:513-520.
59. Brenner M.K., et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993, 341:85-86.
60. Brenner M.K., et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993, 342:1134-1137.
61. Rill D.R., et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992, 79:2694-2700.
62. Rill D.R., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
63. Rill D.R., et al. Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther 1992, 3:129-136.
64. Deisseroth A.B., et al. Genetic marking shows that Ph+ cell present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994, 83:3068-3076.
65. Alici E., et al. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther 2007, 14:227-232.
66. Dunbar C.E., et al. Retrovirally-marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995, 85:3048-3057.
67. Emmons R.V., et al. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 1997, 89:4040-4046.
68. Bachier C.R., et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 1999, 32:279-288.
69. Cornetta K., et al. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum Gene Ther 1996, 7:1323-1329.
70. Blaese R.M., et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270:475-480.
71. Culver K., et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci U S A 1991, 88:3155-3159.
72. Bordignon C., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995, 270:470-475.
73. Hoogerbrugge P.M., et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996, 3:179-183.
74. Kohn D.B., et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995, 1:1017-1023.
75. Dunbar C.E., et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998, 9:2629-2640.
76. Malech H.L., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997, 94:12133-12138.
77. Abkowitz J.L., et al. Behavior of hematopoietic stem cells in a large animal. Proc Natl Acad Sci U S A 1995, 92:2031-2035.
78. Abkowitz J.L., Catlin S.N., Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med 1996, 2:190-197.
79. Abkowitz J.L., Golinelli D., Harrison D.E., Guttorp P. In vivo kinetics of murine hemopoietic stem cells. Blood 2000, 96:3399-3405.
80. Catlin S.N., Busque L., Gale R.E., Guttorp P., Abkowitz J.L. The replication rate of human hematopoietic stem cells in vivo. Blood 2011, 117:4460-4466.
81. Shepherd B.E., Guttorp P., Lansdorp P.M., Abkowitz J.L. Estimating human hematopoietic stem cell kinetics using granulocyte telomere lengths. Exp Hematol 2004, 32:1040-1050.
82. Mohrin M., et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010, 7:174-185.
83. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10:4239-4242.
84. Orlic D., et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A 1996, 93:11097-11102.
85. Bryder D., Bjorgvinsdottir H., Sasaki Y., Jacobsen S.E. Deficiency of oncoretrovirally transduced hematopoietic stem cells and correction through ex vivo expansion. J Gene Med 2005, 7:137-144.
86. Peters S.O., Kittler E.L., Ramshaw H.S., Quesenberry P.J. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 1996, 87:30-37.
87. Peters S.O., Kittler E.L.W., Ramshaw H.S., Quesenberry P.J. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 1995, 23:461-466.
88. Gan O.I., Murdoch B., Larochelle A., Dick J.E. Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 1997, 90:641-650.
89. Gothot A., van der Loo J.C.M., Clapp D.W., Srour E.F. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34+ cells in non-obese diabetic/ severe combined immune-deficient mice. Blood 1998, 92:2641-2649.
90. Takatoku M., et al. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J Clin Invest 2001, 108:447-455.
91. Larochelle A., et al. Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood 2012, 119:1848-1855.
92. Glimm H., Oh I.H., Eaves C.J. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 2000, 96:4185-4193.
93. Zanjani E.D., et al. Engraftment and long-term expression of human fetal hemopoietic stem cells in sheep following transplantation in utero. J Clin Invest 1992, 89:1178-1188.
94. Zanjani E.D., Flake A.W., Rice H., Hedrick M., Tavassoli M. Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep. J Clin Invest 1994, 93:1051-1055.
95. Zanjani E.D., Almeida-Porada G., Flake A.W. The human/sheep xenograft model: a large animal model of human hematopoiesis. Int J Hematol 1996, 63:179-192.
96. Porada C.D., et al. Transduction of long-term-engrafting human hematopoietic stem cells by retroviral vectors. Hum Gene Ther 2002, 13:867-879.
97. Donahue R.E., Dunbar C.E. An update on the use of non-human primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther 2001, 12:607-617.
98. Donahue R.E., et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992, 176:1125-1135.
99. Kamel-Reid S., Dick J.E. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988, 242:1706-1709.
100. Lapidot T., et al. Cytokine stimulation of multilineage hematopoietsis from immature human cells engrafted in SCID mice. Science 1992, 255:1137-1141.
101. Shultz L.D., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995, 154:180-191.
102. null) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 2000, 95:3102-3105.
103. Kerre T.C., et al. Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. Blood 2002, 99:1620-1626.
104. Shultz L.D., et al. Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells. Exp Hematol 2003, 31:551-558.
105. Hiramatsu H., et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 2003, 102:873-880.
106. Ito M., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
107. Shultz L.D., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489.
108. Guenechea G., Gan O.I., Dorrell C., Dick J.E. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol 2001, 2:75-82.
109. Notta F., et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
110. Glimm H., et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest 2001, 107:199-206.
111. Horn P.A., et al. Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice versus nonhuman primates. Blood 2003, 102:4329-4335.
112. Bukrinsky M.I., et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
113. Case S.S., et al. Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 1999, 96:2988-2993.
114. Follenzi A., Ailles L.E., Bakovic S., Geuna M., Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000, 25:217-222.
115. Gallay P., Swingler S., Aiken C., Trono D. HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995, 80:379-388.
116. Gallay P., Hope T., Chin D., Trono D. Hiv-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A 1997, 94:9825-9830.
117. Goff S.P. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med 2001, 3:517-528.
118. Heinzinger N.K., et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 1994, 91:7311-7315.
119. Popov S., Rexach M., Ratner L., Blobel G., Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998, 273:13347-13352.
120. Sirven A., et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000, 96:4103-4110.
121. Zennou V., et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101:173-185.
122. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997, 15:871-875.
123. Korin Y.D., Zack J.A. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998, 72:3161-3168.
124. Sutton R.E., Reitsma M.J., Uchida N., Brown P.O. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 1999, 73:3649-3660.
125. Uchida N., et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated Go/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A 1998, 95:11939-11944.
126. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
127. Cronin J., Zhang X.Y., Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005, 5:387-398.
128. Kelly P.F., Vandergriff J., Nathwani A., Nienhuis A.W., Vanin E.F. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000, 96:1206-1214.
129. Marandin A., et al. Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 1998, 9:1497-1511.
130. Movassagh M., et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 1998, 9:225-234.
131. Porter C.D., et al. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther 1996, 7:913-919.
132. Guenechea G., et al. Transduction of human CD34+CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther 2000, 1:566-573.
133. Liu Y., et al. Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34(+) NOD/SCID-repopulating cells. Exp Hematol 2008, 36:947-956.
134. Miyoshi H., Smith K.A., Mosier D.E., Verma I.M., Torbett B.E. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999, 283:682-686.
135. Piacibello W., et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997, 89:2644-2653.
136. Woods N.B., et al. Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood 2000, 96:3725-3733.
137. Benhamida S., et al. Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther 2003, 7:317-324.
138. Tesio M., et al. Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. Stem Cells 2008, 26:1620-1627.
139. Piacibello W., et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood 2002, 100:4391-4400.
140. Puthenveetil G., et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004, 104:3445-3453.
141. Asheuer M., et al. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci U S A 2004, 101:3557-3562.
142. Cartier N., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
143. Boztug K., et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010, 363:1918-1927.
144. Galy A., Thrasher A.J. Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin. Allergy Clin Immunol 2011, 11:545-550.
145. Scaramuzza S., et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther 2013, 21:175-184.
146. Naumann N., et al. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft. Gene Ther 2007, 14:1513-1524.
147. Roesler J., et al. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood 2002, 100:4381-4390.
148. Lagresle-Peyrou C., et al. Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients. Mol Ther 2008, 16:396-403.
149. Hofling A.A., Devine S., Vogler C., Sands M.S. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther 2004, 9:856-865.
150. An D.S., et al. Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol 2001, 75:3547-3555.
151. An D.S., et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34+ cells. J Virol 2000, 74:1286-1295.
152. Horn P.A., et al. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther 2002, 9:1464-1471.
153. Horn P.A., et al. Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 2004, 103:3710-3716.
154. Trobridge G.D., et al. Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood 2008, 111:5537-5543.
155. Hanawa H., et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 2004, 103:4062-4069.
156. Kim Y.J., et al. Sustained high level polyclonal hematopoietic marking and transgene expression four years following autologous transplantation of rhesus macaques with SIV lentiviral vector transduced CD34+ cells. Blood 2009, 113:5434-5443.
157. Larochelle A., et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 2009, 119:1952-1963.
158. Tarantal A.F., et al. Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. Mol Ther 2012, 20:1033-1045.
159. Verhoeyen E., et al. Stem cell factor-displaying SIV vectors together with a low conditioning regimen allow for long-term engraftment of gene marked autologous HSCs in macaques. Hum Gene Ther 2012, 23:754-768.
160. Kootstra N.A., Munk C., Tonnu N., Landau N.R., Verma I.M. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A 2003, 100:1298-1303.
161. Rits M.A., van Dort K.A., Munk C., Meijer A.B., Kootstra N.A. Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol Ther 2007, 15:930-937.
162. Uchida N., et al. Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol 2009, 83:9854-9862.
163. Hayakawa J., et al. Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Hum Gene Ther 2009, 20:563-572.
164. Bauer T.R., Adler R.L., Hickstein D.D. Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems. ILAR J 2009, 50:168-186.
165. Boudreaux M.K., Clinical D.L. biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs. Vet Pathol 2001, 38:249-260.
166. Fang J., et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A 2011, 108:9583-9588.
167. Ting-De Ravin S.S., et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood 2006, 107:3091-3097.
168. Bauer T.R., et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 2006, 108:3313-3320.
169. Bauer T.R., et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008, 14:93-97.
170. Astrakhan A., et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012, 119:4395-4407.
171. Blundell M.P., et al. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy. Mol Ther 2008, 16:836-844.
172. Bosticardo M., et al. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2011, 127:1376-1384.
173. Charrier S., et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2005, 12:597-606.
174. Dupre L., et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006, 17:303-313.
175. Marangoni F., et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther 2009, 17:1073-1082.
176. Imren S., et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A 2002, 99:14380-14385.
177. Negre O., et al. Correction of murine beta-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. Blood 2011, 117:5321-5331.
178. Persons D.A., et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003, 102:506-513.
179. Zhao H., et al. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 2009, 113:5747-5756.
180. Almarza E., et al. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. Mol Ther 2007, 15:1487-1494.
181. Benjelloun F., et al. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther 2008, 16:1490-1499.
182. Mostoslavsky G., Fabian A.J., Rooney S., Alt F.W., Mulligan R.C. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A 2006, 103:16406-16411.
183. Zhang F., et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007, 110:1448-1457.
184. Zhou S., et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 2010, 116:900-908.
185. Barde I., et al. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther 2011, 18:1087-1097.
186. Pujol A., et al. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 2002, 11:499-505.
187. Dao M.A., Hannum C.H., Kohn D.B., Nolta J.A. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated trasduction. Blood 1997, 89:446-456.
188. Borge O.J., Ramsfjell V., Cui L., Jacobsen S.E.W. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single cell level: key role of thrombopoietin. Blood 1997, 90:2282-2292.
189. Borge O.J., et al. Thrombopoietin, but not erythtopoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood 1996, 88:2859-2870.
190. Kiem H.P., et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 1998, 92:1878-1886.
191. Kurre P., et al. Gene transfer into baboon repopulating cells: a comparison of Flt-3 ligand and megakaryocyte growth and development factor versus IL-3 during ex vivo transduction. Mol Ther 2001, 3:920-927.
192. Wu T., et al. Prolonged high-level detection of retrovirally-marked hematopoietic cells in non-human primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther 2000, 1:285-293.
193. Wognum A.W., Visser T.P., Peters K., Bierhuizen M.F., Wagemaker G. Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells. Hum Gene Ther 2000, 11:2129-2141.
194. Yonemura Y., Ku H., Hirayama F., Souza L.M., Ogawa M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci U S A 1996, 93:4040-4044.
195. Leuci V., et al. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. J Biotechnol 2011, 156:218-226.
196. Santoni de Sio F.R., Cascio P., Zingale A., Gasparini M., Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006, 107:4257-4265.
197. Moore K.A., Deisseroth A.B., Reading C.L., Williams D.E., Belmont J.W. Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture initiating cells. Blood 1992, 79:1393-1399.
198. Wells S., Malik P., Pensiero M., Kohn D.B., Nolta J.A. The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease. Gene Ther 1995, 2:512-520.
199. Xu L.C., et al. Growth factors and stromal support generate very efficient retroviral transduction of peripheral blood CD34+ cells from Gaucher patients. Blood 1995, 86:141-146.
200. Tisdale J.F., et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998, 92:1131-1141.
201. Moritz T., Patel V.P., Williams D.A. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest 1994, 93:1451-1457.
202. Carstanjen D., Dutt P., Moritz T. Heparin inhibits retrovirus binding to fibronectin as well as retrovirus gene transfer on fibronectin fragments. J Virol 2001, 75:6218-6222.
203. Hanenberg H., et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996, 2:876-882.
204. Lei P., Bajaj B., Andreadis S.T. Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin. J Virol 2002, 76:8722-8728.
205. Relander T., Karlsson S., Richter J. Oncoretroviral gene transfer to NOD/SCID repopulating cells using three different viral envelopes. J Gene Med 2002, 4:122-132.
206. Kotani H., et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994, 5:19-28.
207. Dao M.A., Hashino K., Kato I., Nolta J.A. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 1998, 92:4612-4621.
208. Sagar B.M., Rentala S., Gopal P.N., Sharma S., Mukhopadhyay A. Fibronectin and laminin enhance engraftibility of cultured hematopoietic stem cells. Biochem Biophys Res Commun 2006, 350:1000-1005.
209. Yokota T., et al. Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirements for fibronectin activities of CS1 and cell-binding domains. Blood 1998, 91:3263-3272.
210. Donahue R.E., et al. Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells. Mol Ther 2001, 3:359-367.
211. Abonour R., et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000, 6:652-658.
212. Hanenberg H., et al. Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 1997, 8:2193-2206.
213. Lee H.J., et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009, 37:203-209.
214. Schiffman R., et al. Transfer of the human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipients: successful engraftment and long-term expression of the transgene. Blood 1995, 86:1218-1227.
215. Barese C., et al. Granulocyte colony-stimulating factor prior to nonmyeloablative irradiation decreases murine host hematopoietic stem cell function and increases engraftment of donor marrow cells. Stem Cells 2007, 25:1578-1585.
216. Goebel W.S., et al. A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation: biologic insights and potential applications. Exp Hematol 2004, 32:1255-1264.
217. Goebel W.S., Yoder M.C., Pech N.K., Dinauer M.C. Donor chimerism and stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: effects of a retroviral-mediated gene transfer protocol and implications for gene therapy. Exp Hematol 2002, 30:1324-1332.
218. Goebel W.S., Pech N.K., Dinauer M.C. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease. Blood Cells Mol Dis 2004, 33:365-371.
219. Huston M.W., et al. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol. Ther 2011, 19:1867-1877.
220. Czechowicz A., Kraft D., Weissman I.L., Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007, 318:1296-1299.
221. Xue X., et al. Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice. Blood 2010, 116:5419-5422.
222. Chen J., et al. Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood 2006, 107:3764-3771.
223. Carter R.F., et al. Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. Blood 1992, 79:356-364.
224. Huhn R.D., et al. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative contitioning. Hum. Gene Ther 1999, 10:1783-1790.
225. Kahl C.A., et al. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp. Hematol 2006, 34:369-381.
226. Kang E.M., et al. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp. Hematol 2006, 34:132-139.
227. Rosenzweig M., et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood 1999, 94:2271-2286.
228. Sadat M.A., et al. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Ther 2009, 16:1452-1464.
229. Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
230. Aiuti A., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med 2009, 360:447-458.
231. Gaspar H.B., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med 2011, 3. 97ra80.
232. Gaspar H.B., et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med 2011, 3. 97ra79.
233. Gaspar H.B., et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther 2006, 14:505-513.
234. Kang E.M., et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115:783-791.
235. Kang H.J., et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol. Ther 2011, 19:2092-2101.
236. Ott M.G., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med 2006, 12:401-409.
237. Millington M., Arndt A., Boyd M., Applegate T., Shen S. Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS. One 2009, 4. e6461.
238. Uchida N., et al. Optimal conditions for lentiviral transduction of engrafting human CD34+ cells. Gene Ther 2011, 18:1078-1086.
239. Dunbar C.E., Larochelle A. Gene therapy activates EVI1, destabilizes chromosomes. Nat. Med 2010, 16:163-165.
240. Cavazzana-Calvo M., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
241. Chinen J., et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 2007, 110:67-73.
242. Gaspar H.B., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364:2181-2187.
243. Hacein-Bey-Abina S., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med 2010, 363:355-364.
244. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med 2002, 346:1185-1193.
245. Thrasher A.J., et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005, 105:4255-4257.
246. Stein S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med 2010, 16:198-204.
247. Paruzynski A, et al. High-Level Clustering of Vector Integrations in the German WAS Clinical Gene Therapy Trial. Mol Ther 20(Suppl.1), S212. 5-1-2012. Ref Type: Generic.
248. Hacein-Bey-Abina S., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
249. Hacein-Bey-Abina S., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest 2008, 118:3132-3142.
250. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
251. Schwarzwaelder K., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest 2007, 117:2241-2249.
252. Howe S.J., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest 2008, 118:3143-3150.
253. Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
254. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr. Opin. Hematol 2007, 14:337-342.
255. Mazurier F., Gan O.I., McKenzie J.L., Doedens M., Dick J.E. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 2004, 103:545-552.
256. Miyoshi H., Smith K.A., Mosier D.E., Verma I.M., Torbett B.E. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999, 283:682-686.
257. Nienhuis A.W., Dunbar C.E., Sorrentino B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther 2006, 13:1031-1049.
258. Ikeda K, Mason, PJ, Bessler, M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood (2011).
259. Schmidt M., et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat. Med 2003, 9:463-468.
260. Inoue N., et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 2006, 108:4232-4236.
261. Murakami Y., et al. Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria. Br. J. Haematol 2012, 156:383-387.
262. Baum C., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101:2099-2114.
263. Mucenski M.L., et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol. Cell Biol 1988, 8:301-308.
264. Suzuki T., et al. New genes involved in cancer identified by retroviral tagging. Nat. Genet 2002, 32:166-174.
265. Li Z., et al. Murine leukemia induced by retroviral gene marking. Science 2002, 296:497.
266. Bunting K.D., Galipeau J., Topham D., Benaim E., Sorrentino B.P. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 1998, 92:2269-2279.
267. Will E., et al. Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol. Ther 2007, 15:782-791.
268. Kohn D.B., et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther 2003, 8:180-187.
269. Kustikova O., et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308:1171-1174.
270. Schmidt M., et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum. Gene Ther 2001, 12:743-749.
271. Wang G.P., et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010, 115:4356-4366.
272. Li C.L., Xiong D., Stamatoyannopoulos G., Emery D.W. Genomic and Functional Assays Demonstrate Reduced Gammaretroviral Vector Genotoxicity Associated With Use of the cHS4 Chromatin Insulator. Mol. Ther. 2009.
273. Du D., Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary murine bone marrow progenitor cells. Blood 2005, 106:3932-3939.
274. Modlich U., et al. Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108:2545-2553.
275. Kustikova O.S., et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood 2007, 109:1897-1907.
276. Modlich U., et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005, 105:4235-4246.
277. Akagi K., Suzuki T., Stephens R.M., Jenkins N.A., Copeland N.G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004, 32:D523-D527.
278. Erkeland S.J., et al. Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. Cancer Res 2006, 66:622-626.
279. Montini E., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol 2006, 24:687-696.
280. Montini E., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest 2009, 119:964-975.
281. Biffi A., et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011, 117:5332-5339.
282. Calmels B., et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005, 106:2530-2533.
283. Hematti P., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS. Biol 2004, 2:e423.
284. Dave U.P., Jenkins N.A., Copeland N.G. Gene therapy insertional mutagenesis insights. Science 2004, 303:333.
285. Woods N.B., Bottero V., Schmidt M., von K.C., Verma I.M. Gene therapy: therapeutic gene causing lymphoma. Nature 2006, 440:1123.
286. Kiem H.P., et al. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol. Ther 2004, 9:389-395.
287. Seggewiss R., et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006, 107:3865-3867.
288. Xie J., et al. Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate. Hum. Gene Ther 2010, 21:695-703.
289. Beard B.C., et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum. Gene Ther 2007, 18:423-434.
290. Hu J., et al. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol. Ther 2008, 9:1617-1623.
291. Antonchuk J., Sauvageau G., Humphries R.K. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 2002, 109:39-45.
292. Zhang X.B., et al. Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. PLoS. Med 2006, 3:e173.
293. Murnane R., et al. Myelodysplasia in 2 pig-tailed macaques (Macaca nemestrina) associated with retroviral vector-mediated insertional mutagenesis and overexpression of HOXB4. Vet. Pathol 2011, 48:999-1001.
294. Zhang X.B., et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J. Clin. Invest 2008, 118:1502-1510.
295. Di S.A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med 2011, 365:1673-1683.
296. Straathof K.C., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
297. Frecha C., Szecsi J., Cosset F.L., Verhoeyen E. Strategies for targeting lentiviral vectors. Curr. Gene Ther 2008, 8:449-460.
298. Porteus M.H., Carroll D. Gene targeting using zinc finger nucleases. Nat. Biotechnol 2005, 23:967-973.
299. Paques F., Duchateau P., Meganucleases D.N.A. double-strand break-induced recombination: perspectives for gene therapy. Curr. Gene Ther 2007, 7:49-66.
300. Boch J. TALEs of genome targeting. Nat. Biotechnol 2011, 29:135-136.
301. Szabo E., et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010.
302. Kohn D.B., et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med 1998, 4:775-780.
303. Hesdorffer C., et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol 1998, 16:165-172.
304. Kohn D.B., et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999, 94:368-371.
305. Cowan K.H., et al. Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. Clin. Cancer Res 1999, 5:1619-1628.
306. Liu J.M., et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi Anemia Group C gene (FANCC). Hum. Gene Ther 1999, 10:2337-2346.
307. Amado R.G., et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther 2004, 15:251-262.
308. Mitsuyasu R.T., Zack J.A., MacPherson J.L., Symonds G.P. Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int 2011, 2011:393698.
309. Mitsuyasu R.T., et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med 2009, 15:285-292.